Neurocrine Biosciences Inc Capital Reinvestment Ratio
Neurocrine Biosciences Inc capital reinvestment ratio. Neurocrine Biosciences Inc (NBIX) has a Capital Reinvestment Ratio of 0.01x as of December 2025, meaning it reinvests 0% of its operating cash flow ($388.40 Million) in capital expenditures ($2.40 Million). See Neurocrine Biosciences Inc (NBIX) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Neurocrine Biosciences Inc (1996–2025)
Capital reinvestment ratio of Neurocrine Biosciences Inc from 1996 to 2025. This chart tracks Neurocrine Biosciences Inc's Capital Reinvestment Ratio across 12 annual periods. See Neurocrine Biosciences Inc (NBIX) financial flexibility to measure the company's free cash flow as a share of total liabilities.
Neurocrine Biosciences Inc Capital Reinvestment Ratio by Year (1996–2025)
Neurocrine Biosciences Inc capital reinvestment ratio by year from 1996 to 2025. For the full cash flow conversion analysis, see cash flow conversion of Neurocrine Biosciences Inc.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.04x | $782.70 Million | $34.00 Million | ▼ -32.3% |
| 2024 | 0.06x | $595.40 Million | $38.20 Million | ▼ -11.6% |
| 2023 | 0.07x | $389.90 Million | $28.30 Million | ▲ +49.3% |
| 2022 | 0.05x | $339.40 Million | $16.50 Million | ▼ -46.7% |
| 2021 | 0.09x | $256.50 Million | $23.40 Million | ▲ +91.2% |
| 2020 | 0.05x | $228.50 Million | $10.90 Million | ▼ -52.3% |
| 2019 | 0.10x | $147.00 Million | $14.70 Million | ▼ -59.1% |
| 2018 | 0.24x | $101.40 Million | $24.80 Million | ▲ +3777.7% |
| 2010 | 0.01x | $49.94 Million | $315.00K | ▼ -99.5% |
| 2003 | 1.36x | $37.13 Million | $50.44 Million | ▲ +133.5% |
| 1997 | 0.58x | $11.00 Million | $6.40 Million | ▲ +143.6% |
| 1996 | 0.24x | $6.70 Million | $1.60 Million | — |